Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib with Irinotecan and Cetuximab in BRAF Mutant Colorectal Cancer
NCT02164916Phase 2Completed
- Sponsor
- SWOG Cancer Research Network
- Start
- Nov 2014
- Primary completion
- Nov 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vemurafenib in colorectal cancer (CRC), sponsored by SWOG Cancer Research Network. Started Nov 2014; status: completed.
02
Drugs
vemurafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02164916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02164916.